Albert Labs, a privately held psychedelic drug developer, signed a letter of intent (LOI) on January 5 to be acquired by ME Resource Corp (CSE:MEC) (OTC:MEEXF), the latter company announced.
The first-ever psychedelics ETF will launch next week, backed by a Canadian fund manager
The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilize psychedelics.
Numinus Announces Listing of New Warrants
Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.
Illinois Awards $31.5 Million In Marijuana-Funded Grants To Repair Communities Harmed By Drug War
Illinois officials announced on Thursday that the state is distributing $31.5 million in grants funded by marijuana tax revenue to communities that have been disproportionately impacted by the war on drugs.
Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond
The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.
Polarized U.S., delayed recovery, inflation: Gold price to 'maintain high prices' in 2021 – StoneX
(Kitco News) Gold remains an attractive investment this year as people opt for inflation-hedge options amid a myriad of risks, including a still divided U.S., according to StoneX.
MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.
Unique magic mushroom microdosing study to begin in Australia
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics.
New clinical trial to explore DMT as treatment for substance use disorders
The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
Congressman Files First Federal Marijuana Reform Bill Of 2021
The first marijuana reform bill of the new Congress was introduced this week.
Gold, silver rally as metals bulls gain momentum
Gold and silver futures prices are sharply higher and near their daily highs at midday Wednesday, on chart-based buying and bets being placed on “the inflation trade.”
